Related Experiment Video

Updated: Jul 13, 2026

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
10:21

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

13.7K

Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?

Elizabeth Nally1, Matthew Young1, Connor Wells1

  • 1Barts Cancer Institute, Queen Mary University of London, London, UK.

European Urology Focus
|June 2, 2024
PubMed

Insights

Antibody-drug conjugates are revolutionizing urothelial cancer (UC) treatment. Enfortumab vedotin is now the standard for advanced UC, with HER2-targeted therapies under investigation.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) have significantly advanced urothelial cancer (UC) treatment.
  • Enfortumab vedotin has emerged as a new standard of care for advanced UC.

Purpose of the Study:

  • To review the impact of ADCs in UC treatment.
  • To highlight the role of enfortumab vedotin in first-line advanced UC.
  • To discuss emerging HER2-targeted therapies for UC.

Main Methods:

  • Literature review of clinical trials and treatment guidelines.
  • Analysis of efficacy and safety data for enfortumab vedotin.
  • Exploration of preclinical and clinical data for HER2-targeted agents.

Main Results:

  • Enfortumab vedotin is established as the first-line standard of care for advanced UC.
  • Ongoing research is exploring personalized treatment strategies targeting HER2 in UC.

Conclusions:

  • ADCs represent a major therapeutic advance in urothelial cancer.
  • Enfortumab vedotin has redefined first-line treatment for advanced UC.
  • Targeting HER2 offers a promising avenue for future personalized UC therapies.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:29

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

102

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...